News Release 

Insilico Medicine to present at Oxford Global Webinar

Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine, to present "Machine Learning: From Omics Data, Novel Targets and Biomarker development to Better Medicines" on a live Oxford Global Webinar

InSilico Medicine, Inc.


IMAGE: Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine, to present "Machine Learning: From Omics Data, Novel Targets and Biomarker development to Better Medicines " on a live Oxford Global Webinar... view more 

Credit: Insilico Medicine

Monday, July 8, 2019 - Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity on a live Oxford Global Webinar on July 9th, at 2 pm BST.

The Webinar was planned in the lead up to the 3rd Annual Artificial Intelligence in Drug Development Congress as part of the spotlight profiles series, in order to tell more about the speakers and the work they do. The event will take place in London, on September 25-26.

The Webinar will go live on the 9th of July 2019, at 2 PM BST.

The Webinar registration link will expire after the live webinar. If you are unable to register in time, please contact Danielle Dalby for a copy of the webinar recording

Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments. At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the applications of deep adversarial networks and reinforcement learning for molecular de novo design and biomarker research. It will also briefly cover Insilico's drug discovery pipeline and platforms and present applications of machine learning to every step of preclinical drug discovery.

"Machine learning techniques, such as deep generative models and reinforcement learning optimization, play a pivotal role in developing new pharmaceuticals. I am very excited to share our vision and latest results with the audience of the upcoming Oxford Global webinar," said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico Medicine.


For further information, images or interviews, please contact:

Contact: Klug Gehilfe


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.